Boris Freidlin, Ph.D.

Biography

Dr. Freidlin has been a statistician with the National Cancer Institute since 1998. He was appointed chief of the Biostatistics Branch in 2019. Before coming to the NCI, he worked for the Emmes Corporation and the George Washington University Biostatistics Center.  He is currently on the data safety and monitoring boards for the Children's Oncology Group and the Experimental Therapeutics Clinical Trials Network. He serves on the NCI Myeloma, Lymphoma, Leukemia Steering Committees and on the NCI Pediatric Leukemia & Lymphoma and Pediatric Solid Tumor Steering Committees. Dr. Freidlin is co-author of over 100 publications. His research interests include design and analysis of adaptive clinical trials and methodologies for evaluation of new cancer treatments and companion biomarkers. 

Education

• Ph.D., Statistics, George Washington University, Washington, DC
• B.S., Mathematics, University of Maryland, College Park, MD

Selected Publications

1. Korn EL, Allegra CJ, Freidlin B. Phase III Evaluation of Treatment Combinations in Three-Arm Trials. Journal of Clinical Oncology 43(2):226-233, 2025
2. Zhao Y, Yuan Y, Korn EL, Freidlin B. Backfilling patients in phase I dose escalation trials using BOIN.  Clinical Cancer Research 16;30(4):673-679, 2024
3. Freidlin B, Korn EL. Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis? Journal of Clinical Oncology 37:3455-3459, 2019
4. Freidlin B, Korn EL. Biomarker enrichment strategies: Matching trial design to biomarker credentials Nature Reviews Clinical Oncology, 11: 81-90, 2014
5. Freidlin B, McShane LM, Korn EL. Randomized Clinical Trials With Biomarkers: Design Issues. Journal of the National Cancer Institute 102:152-160, 2010

For a complete list of publications, refer to the full NCBI bibliography.